เน็กซ์ลิเสท

• BEMPEDOIC ACID180 milligramต่อ 1 tablet
• EZETIMIBE10 milligramต่อ 1 tablet

ประเภทควบคุม

ยาควบคุมพิเศษ

ข้อบ่งใช้

Hypercholesterolaemia and mixed dyslipidaemia Nexlizet is indicated in adults with primary hypercholesterolaemia (heterozygous familial and nonfamilial) or mixed dyslipidaemia, as an adjunct to diet: • in combination with a statin in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin in addition to ezetimibe (see sections 4.2, 4.3, and 4.4), • alone in patients who are either statin-intolerant or for whom a statin is contraindicated, and are unable to reach LDL-C goals with ezetimibe alone, • in patients already being treated with the combination of bempedoic acid and ezetimibe as separate tablets with or without statin. Cardiovascular disease Nexlizet is indicated in adults with established or at high risk for atherosclerotic cardiovascular disease to reduce cardiovascular risk by lowering LDL-C levels, as an adjunct to correction of other risk factors: • in patients on a maximum tolerated dose of a statin and not adequately controlled with additional ezetimibe treatment or, • in patients who are either statin-intolerant, or for whom a statin is contraindicated, and not adequately controlled with ezetimibe treatment or, • in patients already being treated with the combination of bempedoic acid and ezetimibe as separate tablets. For study results with respect to effects on LDL-C, cardiovascular events and populations studied see section 5.1.

รหัส ATC

- (-)

ข้อมูลตามที่ขึ้นทะเบียนกับ อย. — ไม่ใช่คำแนะนำการใช้ยา ปรึกษาเภสัชกรหรือแพทย์ก่อนใช้เสมอ